Health
Cancer Prevention
2015 IPO

Interpace Diagnostics

$0.75
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) As of 2:39 PM EDT today
$0.00 (0.00%) Today

Why Robinhood?

You can buy or sell IDXG and other stocks, options, ETFs, and crypto commission-free!

About IDXG

Interpace Diagnostics Group, Inc. operates as an bioinformatics company, which engages in the development and commercialization of molecular diagnostic test and pathology services. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment; ThyGenX and PathFinderTG which assesses thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy utilizing a proprietary gene expression assay. Read More The company was founded by John P. Dugan in 1987 and is headquartered in Parsippany, NJ.

Employees
89
Headquarters
Parsippany, New Jersey
Founded
1986
Market Cap
28.65M
Price-Earnings Ratio
Dividend Yield
Average Volume
186.66K
High Today
$0.7875
Low Today
$0.74
Open Price
$0.74
Volume
57.70K
52 Week High
$1.78
52 Week Low
$0.6727

Collections

Health
Cancer Prevention
2015 IPO
US
North America

IDXG News

ReutersAug 15

Edited Transcript of IDXG earnings conference call or presentation 13-Aug-19 12:30pm GMT

11

IDXG Earnings

-$0.11
-$0.09
-$0.08
-$0.06
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
-$0.06 per share
Actual
-$0.10 per share

More IDXG News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.